MarzAA Shows Promise in Hemophilia Animal Models

MarzAA Shows Promise in Hemophilia Animal Models

285426

MarzAA Shows Promise in Hemophilia Animal Models

The investigational medication marzeptacog alfa activated (MarzAA) showed promise at stopping bleeding in animal models of hemophilia. The findings were presented in two posters at the Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) by researchers from Catalyst Biosciences, which is developing MarzAA. MarzAA is a lab-made version of the clotting protein factor VIIa. The medication is designed to be administered by subcutaneous (under-the-skin) injection. It is being developed as an…

You must be logged in to read/download the full post.